{
  "docId": "019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "docSlug": "2cfade3d34acc49c8d5f05063b654956",
  "documentTitle": "ATAI | Investor Presentation Deck | 49 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 49,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 18,
  "notes": "The slide uses a line chart to demonstrate clinical efficacy over 12 weeks.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-19a4-704e-b5bc-b8f4ae0c7550/11",
  "deckHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550",
  "deckJsonHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550.json",
  "deckAnchorHref": "/decks/019de070-19a4-704e-b5bc-b8f4ae0c7550#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.6,
        "x": 0.37,
        "y": 0.28
      },
      "kind": "chart",
      "text": "Clinical trial results showing MADRS score reduction over 12 weeks for 1mg, 10mg, and 25mg doses.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91d0daf8-b27f-4951-b290-7950f1ce4c73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.35,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "list",
      "text": "OWNERSHIP: 22.5% | PRODUCT: Oral Psilocybin (COMP360) | PHARMACOLOGY: 5-HT2A-R agonist | PRODUCT FEATURES: Rapid onset, potential for sustained efficacy after single dose | INDICATIONS: Treatment Resistant Depression, MDD, Anorexia, etc. | STATUS: Phase 2b completed | IP: Proprietary formulation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f2993a2-54a2-4f03-9afa-e51608421693",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.37,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Schedule 13D filed with the SEC as of November 29th, 2021. Note: MADRS = Montgomery-Åsberg Depression Rating Scale.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d114ee4-67cb-423c-977e-36d6f91eada5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.15,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "SUMMARY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5efec4d2-04b2-467d-9535-57303e8ea87e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.37,
        "y": 0.08
      },
      "kind": "title",
      "text": "COMP360 Phase 2b trial showed a rapid, sustained reduction in depressive symptoms",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2fccfed-d3f1-4e03-894b-f5d1ec29cbde",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 11,
      "from": 11,
      "beatId": "6d29f961-9e39-4a39-a0d7-1b89c11529f4",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The presentation highlights progress in developing treatments for mental health disorders, including positive results from clinical trials",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "8ce2d3c7-7de8-4bd6-8c40-b66f8bc3b070",
      "evidence": "The presentation emphasizes the need for effective treatments for mental health disorders",
      "position": 0,
      "objective": "Highlight the urgent need for innovation in depression treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}